长链非编码RNA在肝细胞癌耐药中的研究进展  

Long noncoding RNAs in drug resistance of hepatocellular carcinoma:research progress

作　　者：王蒙蒙 张海婧 程树群 WANG Mengmeng;ZHANG Haijing;CHENG Shuqun(Guangdong Pharmaceutical University,Guangzhou 510006,Guangdong,China;Department of Hepatic Surgery(Ⅵ),The Third Affiliated of Naval Medical University(Second Military Medical University),Shanghai 200438,China)

机构地区：[1]广东药科大学,广州510006 [2]海军军医大学(第二军医大学)第三附属医院肝外六科,上海200438

出　　处：《海军军医大学学报》2024年第7期880-890,共11页Academic Journal of Naval Medical University

基　　金：国家科技部重点研发项目(2022YFC2503700).

摘　　要：肝细胞癌是原发性肝癌中最常见的类型,进展迅速、侵袭力强,治疗方法多样。但因其发生、发展所涉及的基因较多、机制复杂,不可避免地出现了治疗耐药性,导致治疗效果不明显,而耐药相关机制尚未完全明确。lncRNA是一类具有多种生物学功能的新型非编码RNA,能通过基因突变等作用于肝癌的发展、转化和侵袭,同时可以通过影响肿瘤免疫微环境、调节肿瘤细胞生物学功能等参与肝癌耐药。本文对lncRNA在肝细胞癌放化疗、靶向和免疫治疗耐药中的作用机制及相关进展进行综述,以期为解决肝癌耐药提供新思路。Hepatocellular carcinoma is the most common type of primary liver cancer,characterized by rapid progression,strong invasion,and diverse treatments.However,due to the large number of genes involved in its development and complicated mechanism,treatment resistance inevitably emerges,leading to ineffective therapeutic effects.Up to now the drug resistance mechanism has not been completely clarified.Long noncoding RNAs(lncRNAs)are a new class of noncoding RNAs with multiple biological functions,and may be involved in the development,transformation,and invasion of hepatocellular carcinoma through gene mutation,as well as in drug resistance by influencing the immune microenvironment of tumors and regulating the biological functions of tumor cells.In this paper,we reviewed the roles of lncRNAs in the chemotherapy,targeted therapy and immunotherapy resistance of hepatocellular carcinoma,hoping to provide new insight for drug resistance in hepatocellular carcinoma.

关 键 词：肝细胞癌 肿瘤抗药性 长链非编码RNA 化学疗法 靶向治疗 免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤]